{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016991","form_type":"8-K","ticker":"FTLF","cik":"0001374328","company_name":"FITLIFE BRANDS, INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.095726+00:00","generated_at":"2026-05-21T04:43:15.494109+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"confidence":"high","headline":"FitLife Brands Q1 2025 revenue $15.9M (-4% YoY), net income $2.0M, diluted EPS $0.20","bullets":["Total revenue $15.9M, down 4% YoY; net income $2.0M vs $2.2M; diluted EPS $0.20 vs $0.21.","Adjusted EBITDA $3.4M, down 6% YoY; net debt $6.0M (0.4x trailing EBITDA).","Legacy FitLife revenue up 5% YoY; MRC (Dr. Tobias) revenue down 11%; MusclePharm down 6%.","MusclePharm launched Pro Series at Vitamin Shoppe in March; MRC skin care brands declined 14%.","Company sees elevated M&A deal flow; balance sheet deleveraged with $6M cash and $12M term loans."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016991","json":"https://secwatch.observer/filing/0001437749-25-016991.json","markdown":"https://secwatch.observer/filing/0001437749-25-016991.md","text":"https://secwatch.observer/filing/0001437749-25-016991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374328/000143774925016991/0001437749-25-016991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374328/000143774925016991/ftlf20250514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:43:15.494109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}